Preisler H D, Venugopal P
Rush Cancer Institute, Division of Hematology and Oncology, Rush Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.
Cell Prolif. 1995 Jun;28(6):347-56. doi: 10.1111/j.1365-2184.1995.tb00076.x.
In drug-sensitive malignancies, treatment failure is a complex phenomenon resulting from both drug resistance and the rapid regrowth of malignant cells in between cycles of chemotherapy. This phenomenon has been referred to as regrowth resistance, and has been identified as a common impediment to the successful treatment of many neoplastic diseases. This phenomenon has received little attention in the past. The administration of maximally tolerated individual dosages of chemotherapeutic agents, combined with the use of biological response modifiers to slow the regrowth between courses of therapy, would be an effective approach to reduce the regrowth resistance. This also could reduce the emergence of drug resistant clones.
在对药物敏感的恶性肿瘤中，治疗失败是一种复杂现象，其源于耐药性以及化疗周期之间恶性细胞的快速再生长。这种现象被称为再生长抗性，并且已被确定为许多肿瘤性疾病成功治疗的常见障碍。过去，这种现象很少受到关注。给予最大耐受剂量的个体化疗药物，同时使用生物反应调节剂来减缓疗程之间的再生长，将是一种有效减少再生长抗性的方法。这也可以减少耐药克隆的出现。
